SRD5A3-CDG
SRD5A3-CDG
SRD5A3-CDG (pronounced as S-R-D-Five-A-Three-C-D-G) is a rare congenital disorder of glycosylation. It is caused by mutations in the SRD5A3 gene.
Etymology
The term SRD5A3-CDG is an acronym derived from the name of the gene that causes the disorder, SRD5A3, and CDG, which stands for Congenital Disorders of Glycosylation. The SRD5A3 gene is responsible for the production of an enzyme called steroid 5 alpha-reductase 3.
Symptoms
The symptoms of SRD5A3-CDG can vary widely among affected individuals. They may include eye abnormalities, intellectual disability, seizures, and abnormalities in the development of various organs.
Diagnosis
Diagnosis of SRD5A3-CDG is typically made through genetic testing, which can identify mutations in the SRD5A3 gene. Other diagnostic tests may include blood tests to detect abnormalities in the body's process of glycosylation.
Treatment
There is currently no cure for SRD5A3-CDG. Treatment is typically focused on managing the symptoms of the disorder and may include physical therapy, speech therapy, and medication to control seizures.
Prognosis
The prognosis for individuals with SRD5A3-CDG can vary widely, depending on the severity of the symptoms and the individual's overall health. Some individuals may have a normal lifespan, while others may have a shortened lifespan due to complications of the disorder.
See also
External links
- Medical encyclopedia article on SRD5A3-CDG
- Wikipedia's article - SRD5A3-CDG
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski